Choose Your Country or Region

Edoxaban tosylate Monohydrate

Name: Edoxaban tosylate Monohydrate
Brand: Selleck Chemicals
SKU: S7280
Rating: 5 (6 reviews)

Synonyms: DU-176b

Catalog No.S7280 Purity: 99.95%

Edoxaban (DU-176b) is a selective factor Xa inhibitor with K_i of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

Edoxaban tosylate Monohydrate Chemical Structure

CAS: 1229194-11-9

Selleck's Edoxaban tosylate Monohydrate has been cited by 6 publications

Purity & Quality Control

Batch: Purity: 99.95%

99.95

Edoxaban tosylate Monohydrate Related Products

Related Products	Apixaban Rivaroxaban Edoxaban Betrixaban Betrixaban maleate	Click to Expand
Related Compound Libraries	Metabolism Compound Library Anti-cancer Metabolism Compound Library Glutamine Metabolism Compound Library Carbohydrate Metabolism Compound Library Lipid Metabolism Compound Library	Click to Expand

Signaling Pathway

Factor Xa Signaling Pathway

Choose Selective Factor Xa Inhibitors

Biological Activity

Description

Edoxaban (DU-176b) is a selective factor Xa inhibitor with K_i of 0.561 nM, >10 000-fold selectivity over thrombin and FIXa, and is also an orally bioavailable anticoagulant drug.

Targets

Factor Xa ^[1]
(Cell-free assay)

0.561 nM(Ki)

In vitro
In vitro	In human plasma, Edoxaban doubles prothrombin time and activates partial thromboplastin time at 0.256 and 0.508 μM, respectively. ^[1]

In Vivo
In vivo	Oral administration of Edoxaban produces potent anti-Xa activity and high drug concentration in plasma in rats and monkeys. In vivo, Edoxaban dose-dependently inhibits thrombus formation in rat and rabbit thrombosis models. ^[1]
Animal Research	Animal Models	Venous stasis thrombosis model in rats and rabbits
	Dosages	0.3–3 mg/kg (Rabbit); 0.5–12.5 mg/kg (Rat)
	Administration	p.o.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05339672	Recruiting	Drug-drug Interaction	Radboud University Medical Center\|Astellas Pharma Inc	July 1 2024	--
NCT06149533	Not yet recruiting	Thrombosis Venous\|Cancer\|Catheter Complications	Cancer Institute and Hospital Chinese Academy of Medical Sciences	November 30 2023	Phase 3
NCT05869591	Not yet recruiting	Liver Cirrhosis	Centre Hospitalier Universitaire Vaudois	October 2023	Phase 2
NCT05804747	Recruiting	Atrial Fibrillation	Daiichi Sankyo Inc.\|Daiichi Sankyo Korea Co. Ltd.	February 16 2023	--
NCT05122455	Recruiting	SCAD\|AMI	University of Sao Paulo\|Daiichi Sankyo Inc.	September 14 2021	Phase 2\|Phase 3

References

[1] Furugohri T, et al. J Thromb Haemost. 2008, 6(9), 1542-1549.

Chemical Information & Solubility

Molecular Weight	738.27	Formula	C₂₄H₃₀ClN₇O₄S.C₇H₈O₃S.H₂O
CAS No.	1229194-11-9	SDF	Download Edoxaban tosylate Monohydrate SDF
Smiles	CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):